NxStage to Present at the 28th Annual J.P. Morgan Healthcare Conference

Wednesday December 9, 2009

LAWRENCE, Mass., Dec 09, 2009 /PRNewswire-FirstCall via COMTEX/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, and Robert Brown, Chief Financial Officer, will be presenting at the 28(th) Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2010 at the Westin St. Francis Hotel, San Francisco, CA.

NxStage’s investor presentation is scheduled for Wednesday, January 13(th) at 4:30 p.m. (Pacific Time). To listen to the audio webcast of the presentation during the event, please visit: http://www.nxstage.com/ and click on ‘Investor Information.’

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company’s website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to Messrs. Burbank and Brown’s plans to present at this conference. NxStage specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NxStage’s expectations or beliefs as of any date subsequent to the date of this press release.

Contact:
Kristen K. Sheppard, Esq.
Investor Relations
ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.